Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
2006-02-07
2006-02-07
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
C435S007210, C435S007230, C435S961000, C435S962000, C436S501000, C436S518000, C436S536000, C436S821000, C436S825000, C436S064000, C436S087000, C436S161000, C436S175000, C436S177000
Reexamination Certificate
active
06995018
ABSTRACT:
The invention provides methods and compositions for exploiting the discovery that members of the small integrin-binding ligand, n-linked glycoproteins family termed SIBLINGS bind to complement Factor H, and moreover that SIBLINGS proteins, such as BSP, exist in relatively acidic forms. The methods provided can be used to detect SIBLINGS proteins in samples from subjects that are suspected of having tumors or abnormal bone turnover. The invention also provides methods of using SIBLINGS proteins to protect cells from complement mediated lysis. Finally, the discovery allows for the creation of specific binding agents that facilitate the detection of SIBLINGS proteins when they are associated with Factor H.
REFERENCES:
patent: 5049659 (1991-09-01), Cantor et al.
patent: 5180808 (1993-01-01), Ruoslahti
patent: 5306305 (1994-04-01), Lee
patent: 5340934 (1994-08-01), Termine et al.
patent: 5453492 (1995-09-01), Butzow et al.
patent: 5545534 (1996-08-01), Akita et al.
patent: 5693511 (1997-12-01), Harris et al.
patent: 6753314 (2004-06-01), Giot et al.
patent: 09138213 (1997-05-01), None
patent: WO94/13310 (1994-06-01), None
patent: WO 99/50666 (1999-10-01), None
Bellahcéne et al., “Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development,”Journal of Bone and Mineral Research11:665-670, 1996a.
Bellahcéne et al., “Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribonucleic acid levels,”Laboratory Investigation75:203-210, 1996b.
Bellahcéne et al., “Ectopic expression of bone sialoprotein in human thyroid cancer,”Thyroid8:637-641, 1998.
Bellahcéne et al., “Expression of bone matrix proteins in human breast cancer: Potential roles in microcalcification formation and in the genesis of bone metastases,”Bulletin du Cancer84(1):17-24, 1997a.
Bellahcéne et al., “Expression of bone sialoprotein, a bone matrix protein, in human breast cancer,”Cancer Research54:2823-2826, 1994.
Bellahcéne et al., “Expression of bone sialoprotein in human lung cancer,”Calcified Tissue International61:183-188, 1997b.
Bellahcéne et al., “Expression of bone sialoprotein in primary human breast cancer is associated with poor survival,”International Journal of Cancer(Pred. Oncol.) 69:350-353, 1996c.
Bianco et al, “Expression of bone sialoprotein (BSP) in developing human tissues,”Calcified Tissue International49:421-426, 1991.
Bresalier et al., “Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis,”Cancer Research50:1299-1307, 1990.
Ecarot-Charrier et al., “Bone sialoprotein II synthesized by cultured osteoblasts contains tyrosine sulfate,”The Journal of Biological Chemistry264:20049-20053, 1989.
Fisher et al., “Matrix sialoprotein of developing bone,”The Journal of Biological Chemistry258:12723-12727, 1983.
Fisher et al., “Noncollagenous proteins influencing the local mechanisms of calcification,”Clinical Orthopaedics and Related Research200:362-385, 1985.
Fisher et al, “Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone,”The Journal of Biological Chemistry262:9702-9708, 1987.
Gillespie et al., “Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers,”International Journal of Cancer73:812-815, 1997.
Karmatschek et al., “Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay,”Clin Chem43(11):2076-2082, Nov. 1997.
Midura et al., “A rat osteogenic cell line (UMR 106-01) synthesizes a highly sulfated form of bone sialoprotein,”The Journal of Biological Chemistry265:5285-5291, 1990.
Mintz et al., “Chlorate-induced inhibition of tyrosine sulfation on bone sialoprotein synthesized by a rat osteoblast-like cell line (UMR 106-01 BSP),”The Journal of Biological Chemistry269:4845-4852, 1994.
Oldberg et al., “The primary structure of a cell-binding bone sialoprotein,”The Journal of Biological Chemistry263:19430-19432, 1998.
Seibel et al., “Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease,”Journal of Clinical Endocrinology and Metabolism81:3289-3294, 1996.
Senger et al., “Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin,”Biochimica et Biophysica Acta996:43-48, 1989.
Stubbs et al., “Characterization of native and recombinant bone sialoprotein: delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain,”Journal of Bone and Mineral Research12:1210-1222, 1997.
van der Pluijm et al., “Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone,”Cancer Research56:1948-1955, 1996.
Waltregny et al., “Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer,”J Natl Cancer Inst90(13):1000-1008, Jul. 1998.
Withold et al., “Bone sialoprotein in serum of patients with malignant bone diseases,”Clinical Chemistry43:85-91, 1997.
Fedarko et al., “Factor H binding to bone sialoprotein and osteopontin enables tumor cells evasion of complement-mediated attach,”J. Biol. Chem.,vol. 275, No. 22, pp. 16666-16672 (2000).
Fedarko et al., “Integrins and factor H mediate bone sialoprotein's and osteopontin's protective properties in complement attach on susceptible cancer cells,”Journal of Bone and Mineral Research,Twenty First Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, Missouri (Sep. 30-Oct. 4, 1999), vol. 14, No. Suppl. 1, pp. S187 (1999).
Fisher et al., “Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins,”Acta Orthopaedica Scaninavica,vol. 266, pp. 61-65 (1995).
Pritchard et al., “Is the expression of osteopontin and bone sialoprotein greater in breast cancer bone metastases compared to other metastatic sites,”European Symposium on Calcified Tissues,vol. 20, No. 4S, p. 63S (1997).
Fedarko Neal S.
Fisher Larry W.
Young Marian F.
Klarquist & Sparkman, LLP
Saunders David
The United States of America as represented by the Secretary of
LandOfFree
Complex formed by N-linked glycoproteins (SIBLINGS)and Factor H does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complex formed by N-linked glycoproteins (SIBLINGS)and Factor H, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complex formed by N-linked glycoproteins (SIBLINGS)and Factor H will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3635866